Barbara Ingold-Heppner
Overview
Explore the profile of Barbara Ingold-Heppner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1314
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muller M, Ingold-Heppner B, Stocker H, Heppner F, Dittmayer C, Laue M
Lancet
. 2023 Apr;
401(10384):1265.
PMID: 37061265
No abstract available.
2.
Locatelli G, Marques-Ferreira F, Katsoulas A, Kalaitzaki V, Krueger M, Ingold-Heppner B, et al.
Glia
. 2022 Nov;
71(3):616-632.
PMID: 36394300
In the central nervous system (CNS), insulin-like growth factor 1 (IGF-1) regulates myelination by oligodendrocyte (ODC) precursor cells and shows anti-apoptotic properties in neuronal cells in different in vitro and...
3.
Muller M, Ingold-Heppner B, Stocker H, Heppner F, Dittmayer C, Laue M
Lancet
. 2022 Oct;
400(10363):1618.
PMID: 36252575
No abstract available.
4.
Jank P, Gehlhaar C, Lederer B, Fontanella C, Schneeweiss A, Karn T, et al.
PLoS One
. 2021 Sep;
16(9):e0257142.
PMID: 34469495
[This corrects the article DOI: 10.1371/journal.pone.0238021.].
5.
Elezkurtaj S, Greuel S, Ihlow J, Michaelis E, Bischoff P, Kunze C, et al.
Sci Rep
. 2021 Feb;
11(1):4263.
PMID: 33608563
Infection by the new corona virus strain SARS-CoV-2 and its related syndrome COVID-19 has been associated with more than two million deaths worldwide. Patients of higher age and with preexisting...
6.
Priedigkeit N, Ding K, Horne W, Kolls J, Du T, Lucas P, et al.
Breast Cancer Res
. 2021 Jan;
23(1):1.
PMID: 33407744
Background: Endocrine therapy resistance is a hallmark of advanced estrogen receptor (ER)-positive breast cancer. In this study, we aimed to determine acquired genomic changes in endocrine-resistant disease. Methods: We performed...
7.
Meinhardt J, Radke J, Dittmayer C, Franz J, Thomas C, Mothes R, et al.
Nat Neurosci
. 2020 Dec;
24(2):168-175.
PMID: 33257876
The newly identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes COVID-19, a pandemic respiratory disease. Moreover, thromboembolic events throughout the body, including in the CNS, have been described. Given...
8.
Jank P, Gehlhaar C, Bianca L, Caterina F, Andreas S, Karn T, et al.
PLoS One
. 2020 Aug;
15(8):e0238021.
PMID: 32841306
Triple-negative breast cancer (TNBC) is typically treated with chemotherapeutic agents, including carboplatin (Cb), an DNA platinating agent. The O6-methylguanine-DNA-methyltransferase gene (MGMT) encodes for the protein O6-alkylguanine-DNA-alkyltransferase (MGMT protein). MGMT protein...
9.
Laakmann E, Witzel I, Fasching P, Rezai M, Schem C, Solbach C, et al.
Breast Cancer Res
. 2019 May;
21(1):60.
PMID: 31077239
Background: The incidence of central nervous system (CNS) metastases in breast cancer patients is rising and has become a major clinical challenge. Only few data are published concerning risk factors...
10.
Schneeweiss A, Mobus V, Tesch H, Hanusch C, Denkert C, Lubbe K, et al.
Eur J Cancer
. 2018 Dec;
106:181-192.
PMID: 30528802
Background: GeparOcto compared efficacy and safety of two chemotherapy regimens in high-risk early breast cancer (BC): sequential treatment with intense dose-dense epirubicin, paclitaxel, and cyclophosphamide (iddEPC) and weekly treatment with...